Propanc Biopharma, Inc. PPCB
used in this Annual Report on Form 10-K, references to the "Company," "Propanc," "we," "our,"
and "us" refer to Propanc Biopharma, Inc. and its consolidated subsidiary, unless otherwise indicated. In addition, references
to our "financial statements" are to our consolidated financial statements included elsewhere in this Annual Report on Form
10-K except as the context otherwise requires.
Last close
0.28
2026-10-23
Market cap
$15.9M
2026-03-31 share count
52-week range
0.25 - 37.25
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-371.22
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | — | — | — | — | — | — | $28.1K | $30.5K | $29.0K | — |
| R&D | $223.7K | $248.1K | $247.9K | $256.1K | $231.0K | $180.0K | $260.3K | $1.8M | $971.8K | $1.4M |
| SG&A | $57.0M | $1.3M | $1.5M | $1.7M | $1.6M | $3.3M | $2.3M | $2.1M | $4.7M | $5.4M |
| Total operating expenses | $57.3M | $1.5M | $1.8M | $2.0M | $1.8M | $3.5M | $2.6M | $4.0M | $5.7M | $6.9M |
| Operating income | -$57.3M | -$1.5M | -$1.8M | -$2.0M | -$1.8M | -$3.5M | -$2.6M | -$4.0M | -$5.7M | -$6.9M |
| Interest expense | $563.8K | $665.8K | $532.8K | $568.8K | $449.5K | $1.7M | $1.3M | $2.8M | $3.2M | $4.5M |
| Pre-tax income | -$58.9M | -$1.9M | -$2.8M | -$2.7M | -$2.1M | -$4.9M | -$5.8M | -$7.0M | -$7.6M | -$9.3M |
| Income tax | — | $129.1K | $129.8K | $55.0K | $113.4K | $134.7K | $115.4K | $179.3K | $305.7K | $72.5K |
| Net income | -$58.9M | -$1.8M | -$2.7M | -$2.7M | -$2.0M | -$4.7M | -$5.8M | -$7.0M | -$7.9M | -$9.4M |
| EPS, basic | -371.22 | -35,324.35 | -1.80 | -49.23 | -0.80 | — | — | — | — | — |
| EPS, diluted | -371.22 | -35,324.35 | -1.80 | -49.23 | -0.80 | -192.45 | -10.97 | -178.75 | -2.24 | -4.83 |
| Shares, diluted (wtd. avg.) | 158,727 | 57 | 1.7M | 68,219 | 3.0M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | — | — | $4.1K | $2.3K | $67.0K | — | — | — | — |
| Total current assets | $8.4M | $25.4K | $19.0K | $15.0K | $6.6K | $69.0K | $91.1K | $60.9K | $82.0K | $362.8K |
| Property, plant and equipment | — | — | $302 | $2.0K | $4.3K | $5.7K | $8.4K | $8.3K | $10.8K | $12.5K |
| Total assets | $19.6M | $72.4K | $60.3K | $81.7K | $13.1K | $98.5K | $101.7K | $71.4K | $95.1K | $379.1K |
| Accounts payable | $1.2M | $1.2M | $966.7K | $943.0K | $1.0M | $842.2K | $917.3K | $1.2M | $483.5K | $50.0K |
| Total current liabilities | $5.6M | $3.8M | $3.2M | $3.1M | $3.1M | $3.7M | $4.4M | $6.8M | $5.5M | $2.9M |
| Long-term debt | $537.9K | $399.3K | $390.5K | $926.4K | $624.6K | $1.6M | $1.7M | $4.7M | $3.5M | $1.2M |
| Total liabilities | $5.7M | $3.9M | $3.2M | $3.1M | $3.1M | $3.7M | $4.4M | — | — | — |
| Retained earnings | -$125.6M | -$66.7M | -$64.7M | -$61.6M | -$58.2M | -$55.8M | -$51.0M | -$45.3M | -$38.2M | -$30.4M |
| Total equity | $13.9M | -$3.8M | -$3.1M | -$3.0M | -$3.1M | -$3.6M | -$4.3M | -$6.8M | -$5.4M | -$2.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$405.2K | -$935.1K | -$1.1M | -$1.4M | -$1.1M | -$1.8M | -$2.1M | -$2.2M | -$2.1M | -$4.5M |
| Depreciation and amortisation | — | $297 | $1.7K | $2.0K | $2.0K | $2.5K | $2.3K | $2.2K | $2.2K | $877 |
| Stock-based compensation | $4.6M | — | $2.4K | $72.5K | $82.9K | $300.4K | — | $516.1K | $1.7M | $1.7M |
| Capital expenditure | — | — | — | — | — | — | $2.9K | — | — | $9.9K |
| Investing cash flow | — | — | — | — | — | — | -$2.9K | — | — | -$9.9K |
| Financing cash flow | $490.8K | $941.9K | $1.1M | $1.5M | $1.1M | $1.9M | $2.1M | $2.4M | $2.1M | $4.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-033807.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$9.4M | -$7.9M | -$7.0M | -$5.8M | -$4.7M | -$2.0M | -$2.7M | -$2.7M | -$1.8M | -$58.9M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed Item 1.01
- Officer or director change Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Item 5.02
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |